Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | PTPRC | P08575 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6889389 | 0.89 | SIGMAR1 (0.43) | USP2SIGMAR1POLBNPC1RAB9A | |
| SCHEMBL6893352 | 0.85 | SIGMAR1 (0.39) | SIGMAR1LPAR1POLBNPC1RAB9A | |
| SCHEMBL1845666 | 0.81 | MEN1 (0.46) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6899498 | 0.80 | ITGA4 (0.43) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL27559935 | 0.80 | POLB (0.44) | USP2LPAR1POLBTDP1CTSS | |
| SCHEMBL27560049 | 0.80 | POLB (0.44) | USP2LPAR1POLBTDP1CTSS | |
| SCHEMBL27538205 | 0.78 | MMP1 (0.53) | POLBTDP1CTSSCTSLCTSB | |
| SCHEMBL27538204 | 0.78 | MMP1 (0.53) | POLBTDP1CTSSCTSLCTSB | |
| SCHEMBL27538295 | 0.78 | LPAR1 (0.44) | USP2LPAR1POLBTDP1CTSS | |
| SCHEMBL27669824 | 0.77 | TDP1 (0.50) | NPC1RAB9AMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | USP2 163/4885SIGMAR1 26/4885LPAR1 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.